Double-Targeting antibody takes on Hard-to-Treat throat cancer
NCT ID NCT07690787
First seen Jul 08, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This trial tests a new drug called JS207, a bispecific antibody that targets two proteins (PD1 and VEGF) involved in cancer growth and immune evasion. It is being studied in people with recurrent or metastatic nasopharyngeal carcinoma, a type of throat cancer, who have already tried platinum-based chemotherapy. The study first tested JS207 alone, and now combines it with either capecitabine or paclitaxel chemotherapy to see if the combination can shrink tumors and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JS207 (a bispecific antibody targeting PD1 and VEGF) with or without capecitabine or paclitaxel chemotherapy
- What this could lead to
- If successful, this could provide a new treatment option for people with recurrent or metastatic nasopharyngeal carcinoma that has stopped responding to standard chemotherapy.
- What could go wrong
- This is an early-phase trial with only 49 participants, so results may not apply to all patients. The drug may cause side effects or fail to shrink tumors in many participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT/ METASTATIC NPC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Clinical Oncology, Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong